English
Firefly Luciferase CD20 Knockout Raji Cell Line
Firefly Luciferase CD20 Knockout Raji Cell Line
Artikelnummer
BPS82624
Verpackungseinheit
2 vials
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Application: Use as control in CAR-T or NK co-culture killing assays.In vitro and in vivo Bioluminescence Imaging.
Background: The Raji line was established from a Burkitt's lymphoma patient. Raji cells constitutively express the B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T cells.CD20 (also known as B-lymphocyte antigen CD20, or MS4A1) is a non-glycosylated protein expressed on the surface of B-cells during all stages of B-cell development following the pre-B phase. The function and natural ligand of CD20 is not entirely clear. However, CD20 is a marker for several B cell malignancies, including B cell lymphomas, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. Accordingly, several anti-CD20 monoclonal antibodies have been developed to effectively deplete B cell populations and manage B cell malignancies, as well as some inflammatory and autoimmune diseases. The first anti-CD20 monoclonal antibody was Rituximab, which was approved by the FDA in 1997. More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse in cancer patients.Firefly luciferase has been used as a sensitive reporter to study a wide range of biological responses. The signal generated by the firefly luciferase reporter is proportional to Raji cell numbers and facilitates the quantification of Raji cells killing upon co-culture with CAR-T or NK cells.
Description: Firefly Luciferase CD20 Knockout Raji Cell Line is a Raji cell line in which CD20 (B-lymphocyte antigen CD20, or MS4A1) has been genetically removed from Raji cells using CRISPR/Cas9 genome editing, while also constitutively expressing firefly (Photinus pyralis) luciferase under the control of a CMV promoter. This cell line was generated by using Firefly Luciferase Lentivirus (BPS Bioscience #79692) on CD20 Knockout Raji Cell Line (BPS Bioscience #82622).This cell line has been validated by genome sequencing, flow cytometry, and luciferase activity measurement.
Host Cell Line: Raji human B lymphoblastoid cell line, derived from a patient with Burkitt lymphoma. Suspension cells.
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Uniprot: P11836
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
Application: Use as control in CAR-T or NK co-culture killing assays.In vitro and in vivo Bioluminescence Imaging.
Background: The Raji line was established from a Burkitt's lymphoma patient. Raji cells constitutively express the B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T cells.CD20 (also known as B-lymphocyte antigen CD20, or MS4A1) is a non-glycosylated protein expressed on the surface of B-cells during all stages of B-cell development following the pre-B phase. The function and natural ligand of CD20 is not entirely clear. However, CD20 is a marker for several B cell malignancies, including B cell lymphomas, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. Accordingly, several anti-CD20 monoclonal antibodies have been developed to effectively deplete B cell populations and manage B cell malignancies, as well as some inflammatory and autoimmune diseases. The first anti-CD20 monoclonal antibody was Rituximab, which was approved by the FDA in 1997. More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse in cancer patients.Firefly luciferase has been used as a sensitive reporter to study a wide range of biological responses. The signal generated by the firefly luciferase reporter is proportional to Raji cell numbers and facilitates the quantification of Raji cells killing upon co-culture with CAR-T or NK cells.
Description: Firefly Luciferase CD20 Knockout Raji Cell Line is a Raji cell line in which CD20 (B-lymphocyte antigen CD20, or MS4A1) has been genetically removed from Raji cells using CRISPR/Cas9 genome editing, while also constitutively expressing firefly (Photinus pyralis) luciferase under the control of a CMV promoter. This cell line was generated by using Firefly Luciferase Lentivirus (BPS Bioscience #79692) on CD20 Knockout Raji Cell Line (BPS Bioscience #82622).This cell line has been validated by genome sequencing, flow cytometry, and luciferase activity measurement.
Host Cell Line: Raji human B lymphoblastoid cell line, derived from a patient with Burkitt lymphoma. Suspension cells.
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Uniprot: P11836
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
| Artikelnummer | BPS82624 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 82624 |
| Verpackungseinheit | 2 vials |
| Mengeneinheit | PAK |
| Wirt | Human |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
